How Much Does Rezdiffra (Resmetirom) Cost in Iowa in 2026?

Iowa Retail Pricing for Rezdiffra in 2026

The average cash-pay cost for Rezdiffra at Iowa retail pharmacies is $3,500 per month, matching the manufacturer list price set by Madrigal Pharmaceuticals. This price applies to both the 60 mg and 100 mg tablet strengths.

Iowa has approximately 800 licensed retail pharmacies across the state, and pricing for branded specialty drugs shows minimal variation between locations. The $3,500 figure translates to $42,000 annually, placing Rezdiffra in line with other branded therapies for metabolic liver disease. Pharmacies in Des Moines, Cedar Rapids, and Iowa City all report consistent pricing at or near the list figure.

Price differences between pharmacies, when they exist, tend to be marginal. Some independent pharmacies may offer modest discounts through cash-pay negotiation, but the savings rarely exceed 3-5%. For patients filling through mail-order specialty pharmacies, the same $3,500 per month applies unless a discount program is active.

Rezdiffra was approved by the FDA in March 2024 as the first drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH, previously called NASH) with moderate to advanced liver fibrosis (stages F2-F3). The approval was based on surrogate endpoints from the MAESTRO-NASH trial, and Madrigal must complete a confirmatory outcomes trial to retain full approval. This conditional status may influence payer decisions in Iowa and elsewhere.

Iowa Medicaid Does Not Cover Rezdiffra

As of 2026, the Iowa Medicaid program does not include Rezdiffra on its preferred drug list or provide coverage through any formulary pathway. Patients enrolled in Iowa Medicaid who need resmetirom currently have no mechanism to obtain the drug through their Medicaid benefits.

This gap is not unique to Iowa. Many state Medicaid programs have been slow to add Rezdiffra, partly because the drug holds accelerated approval rather than traditional full approval. The distinction matters: accelerated approval is granted based on surrogate endpoints (in this case, NASH resolution and fibrosis improvement on liver biopsy), and the FDA requires confirmatory data showing actual clinical outcomes like reduced progression to cirrhosis or liver transplant.

Iowa's Medicaid formulary committee reviews new drug additions periodically. Patients or providers who want to advocate for coverage can submit written comments during open review periods through the Iowa Department of Health and Human Services. Until Rezdiffra gains formulary status, Iowa Medicaid enrollees face three options: appeal for individual coverage through an exceptions process (success rates are low for drugs not yet on formulary), transition to a commercial plan during open enrollment if eligible, or explore manufacturer assistance programs.

The Endocrine Society's 2023 clinical practice guideline on NAFLD/NASH management notes that pharmacotherapy should be considered for patients with biopsy-confirmed NASH and fibrosis stage F2 or higher. This recommendation could eventually support Medicaid coverage arguments, though Iowa has not yet acted on it.

Commercial Insurance Coverage in Iowa

Several major commercial insurers operating in Iowa do cover Rezdiffra, though virtually all require prior authorization and step therapy documentation. Wellmark Blue Cross Blue Shield, the largest private insurer in Iowa, has established a coverage pathway that typically requires documentation of a liver biopsy or validated noninvasive fibrosis score confirming MASH with F2-F3 fibrosis.

Common prior authorization requirements across Iowa insurers include: confirmed MASH diagnosis with fibrosis staging, evidence that lifestyle modifications (diet, exercise, weight management) have been attempted for at least 6 months, documentation from a hepatologist or gastroenterologist, and baseline liver function testing.

Step therapy may also apply. Some plans require that patients have tried or been deemed ineligible for vitamin E (for non-diabetic NASH) or pioglitazone before approving Rezdiffra. Neither of these older options carries an FDA indication for NASH, but payers still use them as lower-cost first-line requirements.

Copay amounts vary widely based on plan design. Patients with commercial insurance may face monthly copays ranging from $50 to $500 depending on their plan's specialty tier structure. High-deductible health plans can expose patients to the full $3,500 until the deductible is met. For patients on employer-sponsored plans, checking the specific formulary tier and out-of-pocket maximum is the single most important step before filling the prescription.

The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg achieved NASH resolution without worsening of fibrosis in 29.9% of patients versus 9.7% on placebo at 52 weeks, and fibrosis improvement by at least one stage without NASH worsening in 25.9% versus 14.2% on placebo. These results form the clinical foundation for insurance approval arguments. Including these specific numbers in prior authorization letters strengthens the case.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings card for commercially insured patients that can reduce monthly out-of-pocket costs to as low as $0 for eligible individuals. The card is available to Iowa residents who carry commercial insurance (not government-funded plans like Medicare, Medicaid, or Tricare).

Eligibility requirements are straightforward. The patient must have a valid prescription for Rezdiffra, carry commercial drug insurance, and not be enrolled in any federal or state government healthcare program. The savings card covers the difference between the patient's copay or coinsurance and the program floor, up to a maximum annual benefit that Madrigal sets (currently reported at $13,000 per year for most patients).

To enroll, patients or their prescribers can contact Madrigal's patient support hub directly. The card is applied at the pharmacy point of sale. Iowa pharmacies that participate in major pharmacy benefit networks can process the card electronically. Enrollment takes roughly 5-10 business days. Once active, the card renews automatically each calendar year, though Madrigal reserves the right to modify program terms.

For patients whose commercial copay exceeds the savings card's annual cap, the remaining balance reverts to the patient's responsibility. A patient with a $600 monthly copay, for example, would use $7,200 of the $13,000 annual cap in 12 months, staying within the benefit. But a patient with a $1,500 monthly copay would exhaust the cap by month nine. Planning around these thresholds matters.

Patients on Medicare Part D cannot use the savings card due to federal anti-kickback statute restrictions. Medicare beneficiaries should instead contact Madrigal's patient support line to ask about separate assistance programs or explore independent charitable foundations that may cover specialty drug copays.

Compounded Resmetirom Through Iowa 503A Pharmacies

Iowa permits licensed 503A compounding pharmacies to prepare resmetirom formulations for individual patients with valid prescriptions. The legality of compounding resmetirom in Iowa rests on the federal 503A pathway under the Federal Food, Drug, and Cosmetic Act, which allows state-licensed pharmacies to compound drugs for individually identified patients based on a prescriber's order.

A key distinction: 503A compounding is patient-specific. The pharmacy prepares the medication after receiving a prescription for a named patient. This differs from 503B outsourcing facilities, which can produce compounded drugs in larger batches without patient-specific prescriptions.

Pricing for compounded resmetirom varies by pharmacy, but Iowa compounding pharmacies have reported costs significantly below the branded $3,500 price point. Some patients report paying between $200 and $600 per month for compounded versions, though quality, potency testing, and reliability vary between pharmacies.

Patients considering compounded resmetirom should ask the pharmacy several questions: Does the pharmacy hold current Iowa Board of Pharmacy licensure for compounding? Does it perform third-party potency and purity testing on finished preparations? What is the beyond-use date assigned to the compounded product? Is the pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB)?

The Iowa Board of Pharmacy oversees compounding pharmacies in the state and can verify licensure status. Patients should confirm that their chosen pharmacy meets current state and federal compounding standards before filling a prescription. Compounded drugs do not undergo FDA approval review, so the quality assurance responsibility falls more heavily on the pharmacy and the prescribing clinician.

Telehealth Prescribing of Rezdiffra in Iowa

Iowa permits telehealth prescribing of Rezdiffra. Patients can receive a prescription from a licensed provider via video consultation without an in-person visit, provided the prescriber holds an active Iowa medical license or practices under an applicable interstate compact.

Iowa adopted the Interstate Medical Licensure Compact, which allows physicians licensed through the compact to practice telehealth across member states. This expands the pool of hepatologists and gastroenterologists available to Iowa patients, particularly those in rural counties where specialist access is limited. Iowa has 99 counties, and many lack a local gastroenterologist.

For Rezdiffra specifically, the prescribing provider will typically need to review liver biopsy results or noninvasive fibrosis markers (such as FibroScan or FIB-4 score) before writing the prescription. These diagnostic workups may still require an in-person visit to a facility with the appropriate equipment, even if the prescribing appointment itself is virtual.

Telehealth platforms that operate in Iowa and prescribe specialty hepatology medications include both national platforms and Iowa-based health systems with virtual care arms. The University of Iowa Health Care system, for instance, offers telehealth hepatology consultations that can reach patients across the state.

The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends that NASH pharmacotherapy be prescribed by or in consultation with a hepatologist or experienced gastroenterologist. While this is a recommendation rather than a legal requirement, it reflects the standard of care that Iowa telehealth providers should follow.

How to Reduce Your Rezdiffra Costs in Iowa

Reducing the $3,500 monthly cost requires a layered approach. Start with insurance verification. Contact your insurer's specialty pharmacy department and ask specifically whether Rezdiffra is on formulary, what tier it occupies, and what prior authorization criteria apply. Get this in writing.

If your plan covers it, apply for the Madrigal savings card immediately. The card can eliminate copays entirely for patients with moderate coinsurance obligations. Apply before filling the first prescription so the card is active at the point of sale.

If insurance denies coverage, file a formal appeal. Include the MAESTRO-NASH trial data showing statistically significant fibrosis improvement, your diagnostic documentation, and a letter of medical necessity from your hepatologist. Iowa's external review process through the Iowa Insurance Division provides an independent review if the internal appeal fails.

Consider compounded resmetirom as a cost alternative. Iowa's 503A pharmacy infrastructure supports this option, though the clinical equivalence of compounded preparations to branded Rezdiffra has not been independently validated in trials.

Patient assistance foundations are another option. Organizations like the Patient Access Network Foundation and HealthWell Foundation periodically open funds for liver disease medications. These programs typically serve patients at or below 400% of the federal poverty level who have insurance but face high out-of-pocket costs.

For Medicare beneficiaries, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) limits total drug costs. If Rezdiffra gains Medicare formulary placement, this cap would substantially reduce the annual burden from $42,000 to $2,000 maximum.

Clinical Context: Why Rezdiffra Matters for Iowa MASH Patients

MASH affects an estimated 5-6% of U.S. adults, and Iowa's rates of obesity and metabolic syndrome suggest prevalence at or above the national average. Before resmetirom's approval, no FDA-approved pharmacotherapy existed for MASH. Patients relied on weight loss, exercise, and off-label use of vitamin E or pioglitazone.

The MAESTRO-NASH phase 3 trial enrolled 966 patients with biopsy-confirmed NASH and fibrosis stages F1B through F3. At the 100 mg dose, 25.9% achieved fibrosis improvement by at least one stage without worsening of NASH, compared to 14.2% on placebo (P<0.001). NASH resolution without fibrosis worsening occurred in 29.9% versus 9.7% (P<0.001).

Resmetirom works as a thyroid hormone receptor beta (THR-beta) agonist, selectively activating liver THR-beta to increase hepatic fat metabolism and reduce lipotoxic lipid species. This mechanism differs from GLP-1 receptor agonists, which address NASH primarily through weight loss and systemic metabolic improvement. The two drug classes may eventually be used together, though combination data is limited.

Liver-related adverse events in MAESTRO-NASH were infrequent. The most common side effects included diarrhea (27% vs. 18% placebo) and nausea (21% vs. 13% placebo), both typically mild and self-limiting within the first 4-8 weeks of treatment. The FDA label notes that thyroid function should be monitored, as resmetirom can suppress TSH levels, though clinical hypothyroidism was rare in the trial population.

Iowa patients with F2-F3 fibrosis on biopsy or a FibroScan liver stiffness measurement between 8.0 and 13.9 kPa should discuss resmetirom with their hepatologist. Early treatment at the F2-F3 stage aims to prevent progression to cirrhosis (F4), which carries a 5-year liver-related mortality rate of approximately 10-15% according to longitudinal NASH cohort data.